197 related articles for article (PubMed ID: 20890785)
1. The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma.
Levy AG; Zage PE; Akers LJ; Ghisoli ML; Chen Z; Fang W; Kannan S; Graham T; Zeng L; Franklin AR; Huang P; Zweidler-McKay PA
Invest New Drugs; 2012 Feb; 30(1):191-9. PubMed ID: 20890785
[TBL] [Abstract][Full Text] [Related]
2. Targeting glycolysis in leukemia: a novel inhibitor 3-BrOP in combination with rapamycin.
Akers LJ; Fang W; Levy AG; Franklin AR; Huang P; Zweidler-McKay PA
Leuk Res; 2011 Jun; 35(6):814-20. PubMed ID: 21316758
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor activity of 3-bromopyruvate in combination with rapamycin in vivo and in vitro.
Zhang Q; Pan J; Lubet RA; Komas SM; Kalyanaraman B; Wang Y; You M
Cancer Prev Res (Phila); 2015 Apr; 8(4):318-26. PubMed ID: 25644152
[TBL] [Abstract][Full Text] [Related]
4. Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells.
Waetzig R; Matthes M; Leister J; Penkivech G; Heise T; Corbacioglu S; Sommer G
Int J Med Sci; 2021; 18(1):137-149. PubMed ID: 33390782
[TBL] [Abstract][Full Text] [Related]
5. mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling.
Zhang H; Dou J; Yu Y; Zhao Y; Fan Y; Cheng J; Xu X; Liu W; Guan S; Chen Z; shi Y; Patel R; Vasudevan SA; Zage PE; Zhang H; Nuchtern JG; Kim ES; Fu S; Yang J
Apoptosis; 2015 Jan; 20(1):50-62. PubMed ID: 25425103
[TBL] [Abstract][Full Text] [Related]
6. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
[TBL] [Abstract][Full Text] [Related]
7. Effective elimination of cancer stem cells by a novel drug combination strategy.
Yuan S; Wang F; Chen G; Zhang H; Feng L; Wang L; Colman H; Keating MJ; Li X; Xu RH; Wang J; Huang P
Stem Cells; 2013 Jan; 31(1):23-34. PubMed ID: 23132831
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma.
Mohlin S; Hansson K; Radke K; Martinez S; Blanco-Apiricio C; Garcia-Ruiz C; Welinder C; Esfandyari J; O'Neill M; Pastor J; von Stedingk K; Bexell D
EMBO Mol Med; 2019 Aug; 11(8):e10058. PubMed ID: 31310053
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
10. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
11. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
12. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
Guichard SM; Curwen J; Bihani T; D'Cruz CM; Yates JW; Grondine M; Howard Z; Davies BR; Bigley G; Klinowska T; Pike KG; Pass M; Chresta CM; Polanska UM; McEwen R; Delpuech O; Green S; Cosulich SC
Mol Cancer Ther; 2015 Nov; 14(11):2508-18. PubMed ID: 26358751
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
14. Decreased lactate concentration and glycolytic enzyme expression reflect inhibition of mTOR signal transduction pathway in B-cell lymphoma.
Lee SC; Marzec M; Liu X; Wehrli S; Kantekure K; Ragunath PN; Nelson DS; Delikatny EJ; Glickson JD; Wasik MA
NMR Biomed; 2013 Jan; 26(1):106-14. PubMed ID: 22711601
[TBL] [Abstract][Full Text] [Related]
15. Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells.
Wang Y; Wei J; Li L; Fan C; Sun Y
Oncol Res; 2014; 22(4):193-201. PubMed ID: 26351208
[TBL] [Abstract][Full Text] [Related]
16. Epithelial to mesenchymal transition is associated with rapamycin resistance.
Holder AM; Akcakanat A; Adkins F; Evans K; Chen H; Wei C; Milton DR; Li Y; Do KA; Janku F; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(23):19500-13. PubMed ID: 25944619
[TBL] [Abstract][Full Text] [Related]
17. p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy.
Moreno-Smith M; Lakoma A; Chen Z; Tao L; Scorsone KA; Schild L; Aviles-Padilla K; Nikzad R; Zhang Y; Chakraborty R; Molenaar JJ; Vasudevan SA; Sheehan V; Kim ES; Paust S; Shohet JM; Barbieri E
Clin Cancer Res; 2017 Nov; 23(21):6629-6639. PubMed ID: 28821555
[No Abstract] [Full Text] [Related]
18. Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential.
Pelicano H; Zhang W; Liu J; Hammoudi N; Dai J; Xu RH; Pusztai L; Huang P
Breast Cancer Res; 2014 Sep; 16(5):434. PubMed ID: 25209360
[TBL] [Abstract][Full Text] [Related]
19. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.
Mortensen DS; Fultz KE; Xu S; Xu W; Packard G; Khambatta G; Gamez JC; Leisten J; Zhao J; Apuy J; Ghoreishi K; Hickman M; Narla RK; Bissonette R; Richardson S; Peng SX; Perrin-Ninkovic S; Tran T; Shi T; Yang WQ; Tong Z; Cathers BE; Moghaddam MF; Canan SS; Worland P; Sankar S; Raymon HK
Mol Cancer Ther; 2015 Jun; 14(6):1295-305. PubMed ID: 25855786
[TBL] [Abstract][Full Text] [Related]
20. Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma.
Li Z; Yan S; Attayan N; Ramalingam S; Thiele CJ
Clin Cancer Res; 2012 Jul; 18(13):3603-15. PubMed ID: 22550167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
